Unbiased, high-throughput, in vivo screening
gordian.png
 
background-03+with+grad.jpg
 
 

We Are a therapeutics company pioneering a novel screening platform to radically increase the efficiency of development for complex diseases of aginG

 
 
 
Daniel Fuentes

Daniel Fuentes

Martin Borch Jensen

Martin Borch Jensen

Francisco LePort

Francisco LePort

Chris Towne

Chris Towne

 
 
Chris Carrico

Chris Carrico

Ian Driver

Ian Driver

 
 
 

our advisors and Investors span expertise in aging biology, screening technology, Gene Therapy, and biotech corporate strategy

 
 
 
Tom Rando, Stanford (Advisor, Aging Biology)

Tom Rando, Stanford (Advisor, Aging Biology)

Randy Platt, ETH Zurich (Advisor, Genomics)

Randy Platt, ETH Zurich (Advisor, Genomics)

David Schaffer, UC Berkeley (Advisor, Gene Therapy)

David Schaffer, UC Berkeley (Advisor, Gene Therapy)

 
 
Laura Deming (Investor) Managing Partner, Longevity Fund

Laura Deming (Investor) Managing Partner, Longevity Fund

Edward Lanphier (Investor) Founder and CEO at Sangamo Therapeutics (1995 - 2016)

Edward Lanphier (Investor)
Founder and CEO at Sangamo Therapeutics (1995 - 2016)

Thomas Ebeling (Investor) CEO at Novartis (1998 - 2008), Supervisory Board Member at Bayer

Thomas Ebeling (Investor)
CEO at Novartis (1998 - 2008), Supervisory Board Member at Bayer

Alexander III of Macedon (Advisor, Global Scaling)

Alexander III of Macedon (Advisor, Global Scaling)

 
 
longevity+fund.png
50Y-3_large_transparent.png
gordian.png
NJF_LOGO2_1.png
primemoverslab.png
 

 
 

Our mission is audacious, so We work as a team and strive for extraordinary

Read our values, and contact us if you have an exceptional background and ambition in bioinformatics, molecular biology, or gene therapy